Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 5.00% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 16.56% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -28.10% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -36.04% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 46.09% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 11.56% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 13.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.29% |
| Mar 31, 2026 | 64.19% |
| Dec 31, 2025 | 18.55% |
| Sep 30, 2025 | 43.48% |
| Jun 30, 2025 | 100.17% |
| Mar 31, 2025 | -18.51% |
| Dec 31, 2024 | 148.43% |
| Sep 30, 2024 | 75.48% |
| Jun 30, 2024 | 13.05% |
| Mar 31, 2024 | 8.62% |
| Dec 31, 2023 | -25.64% |
| Sep 30, 2023 | 49.35% |
| Jun 30, 2023 | 5.55% |
| Mar 31, 2023 | -59.35% |
| Dec 31, 2022 | 36.31% |
| Sep 30, 2022 | 7.32% |
| Jun 30, 2022 | -32.51% |
| Mar 31, 2022 | 28.61% |
| Dec 31, 2021 | -33.50% |
| Sep 30, 2021 | -23.99% |